Deloitte Names EXALENZ as One of Israel's Companies-to-Watch in the 2014 Deloitte Technology Fast 50™ Awards

MODI'IN, Israel, Sept. 22, 2014 /PRNewswire/ -- EXALENZ Bioscience (TASE: EXEN), a leader in developing and marketing medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, announced today that it was named to the prestigious Deloitte Technology Fast 50, an annual ranking of the 50 fastest-growing technology companies in  Israel for 2014. The Deloitte Technology 50 is a ranking of Israel's 50 fastest-growing technology companies based on percentage growth over five years. The Fast 50 program honors business growth, technological innovation and Israeli entrepreneurial spirit. EXALENZ was honored at the Fast 50 2014 awards ceremony on September 21, 2014 in Tel Aviv, Israel. 

EXALENZ has built a broad footprint in the United States with over 300 medical centers offering its Hp-BreathID test to detect the potentially lethal H. pylori bacterium. Over the last five years, sales reached over ILS 40 million, and the last two years the company's sales volume reached ILS 24.4 million.

"We are proud to be honored as one of the fastest growing technology companies in Israel by Deloitte," said Larry Cohen, CEO of EXALENZ. "Our strong growth over the last five years reflects our team's success at executing and implementing our plan, as well as increased recognition of BreathID's clinical benefits by our customers. The next few years we expect to see continued strong growth fueled by higher sales of BreathID systems in the US, and the anticipated introduction of new diagnostics aimed at significant liver indications such as NASH."

Recently, EXALENZ reported that it is in discussions with several pharmaceutical companies to advance new diagnostic and monitoring tools for NASH (Nonalcoholic Steatohepatitis).  In addition, EXALENZ is developing additional diagnostic and monitoring applications such as   (CSPH) Clinically Significant Portal Hypertension – a dangerous condition that can occur in patients with cirrhosis of the liver, as well as a test for Hepatocellular Carcinoma (HCC).

About EXALENZ Bioscience

EXALENZ Bioscience develops diagnostic and monitoring systems that use the breath to diagnose and help manage GI and liver conditions. The company's flagship BreathID Hp product detects the presence of the H. pylori bacteria the cause of various illnesses including gastric cancer. EXALENZ holds regulatory approvals in Europe the US and Israel for H. pylori detection and is currently in the process of obtaining approvals for additional applications.

Forward-looking information: estimates made by the company included in this publication are considered forward-looking information and there is no assurance that said information will be realized. Company estimates are based on various business assumptions experience and professional information. These estimates may not be realized in whole or in part or may be realized in a manner significantly different from that anticipated by the company for various reasons including reasons not within the control of the company

CONTACT:
David Carey
Lazar Partners Ltd.
T: (212) 867-1768
[email protected]

SOURCE EXALENZ Bioscience